Sonoma Pharmaceuticals (SNOA) Cash & Equivalents (2010 - 2026)
Sonoma Pharmaceuticals (SNOA) posted quarterly Cash & Equivalents of $2.4 million for Q1 2026, down 55.36% year-over-year from $5.4 million in Q1 2025, and down 6.33% quarter-over-quarter from $2.6 million in Q4 2025.
Sonoma Pharmaceuticals (SNOA) Cash & Equivalents (2010 - 2026) Analysis & Trends
Sonoma Pharmaceuticals' Cash & Equivalents history runs 17 years deep, the most recent figure standing at $2.4 million for Q1 2026.
- In Q1 2026, Cash & Equivalents fell 55.36% year-over-year to $2.4 million; the TTM figure through Mar 2026 stood at $2.4 million (down 55.36% YoY), while the FY2026 annual figure was $2.4 million, down 55.36% from the prior year.
- Cash & Equivalents for Q1 2026 stood at $2.4 million, down from $2.6 million in the prior quarter.
- The five-year high for Cash & Equivalents was $7.4 million in Q1 2022, with the low at $2.1 million in Q3 2023.
- The 5-year median for Cash & Equivalents is $3.4 million (2022), against an average of $3.7 million.
- The sharpest annual moves came in 2022 and 2024: Cash & Equivalents slumped 69.12% in 2022, then jumped 117.62% in 2024.
- Sonoma Pharmaceuticals' Cash & Equivalents stood at $2.6 million in 2022, then fell by 8.66% to $2.4 million in 2023, then surged by 117.62% to $5.2 million in 2024, then plunged by 51.09% to $2.6 million in 2025, then slipped by 6.33% to $2.4 million in 2026.
- Business Quant data shows SNOA's Cash & Equivalents at $2.4 million in Q1 2026, $2.6 million in Q4 2025, and $3.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | 1.11 Bn |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | 3.66 Bn |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | 1.48 Bn |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | 2.89 Bn |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | 1.80 Bn |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | 886.50 Mn |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | 332.40 Mn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | 530.00 Mn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | 164.00 Mn |
| 10 | Sonoma Pharmaceuticals | 5.17 Mn | -165,129.89 | 2.58 Mn | 5.34 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 5.34 Mn |
| Mar 31, 2026 | 2.40 Mn |
| Dec 31, 2025 | 2.56 Mn |
| Sep 30, 2025 | 3.04 Mn |
| Jun 30, 2025 | 3.61 Mn |
| Mar 31, 2025 | 5.37 Mn |
| Dec 31, 2024 | 5.24 Mn |
| Sep 30, 2024 | 4.08 Mn |
| Jun 30, 2024 | 2.59 Mn |
| Mar 31, 2024 | 3.13 Mn |
| Dec 31, 2023 | 2.41 Mn |
| Sep 30, 2023 | 2.14 Mn |
| Jun 30, 2023 | 3.54 Mn |
| Mar 31, 2023 | 3.82 Mn |
| Dec 31, 2022 | 2.63 Mn |
| Sep 30, 2022 | 3.35 Mn |
| Jun 30, 2022 | 5.59 Mn |
| Mar 31, 2022 | 7.40 Mn |
| Dec 31, 2021 | 8.53 Mn |
| Sep 30, 2021 | 8.39 Mn |